z-logo
open-access-imgOpen Access
To evaluate correlation of hormone receptors, Ki67 and human epidermal growth factor with other prognostic factors in invasive ductal carcinoma of breast
Author(s) -
Nguyen Van Phu Thang,
Nguyễn Thị Ngọc Ánh,
Ngo Thi Minh Hanh,
Nguyen Duy Hoang,
Nguyễn Quang Thi
Publication year - 2021
Publication title -
y dược lâm sàng 108
Language(s) - English
Resource type - Journals
eISSN - 1859-2880
pISSN - 1859-2872
DOI - 10.52389/ydls.v16ita.1119
Subject(s) - medicine , estrogen receptor , progesterone receptor , invasive ductal carcinoma , breast carcinoma , epidermal growth factor , hormone receptor , oncology , ductal carcinoma , carcinoma , correlation , breast cancer , gynecology , prospective cohort study , immunohistochemistry , human epidermal growth factor receptor 2 , receptor , cancer , geometry , mathematics
Objective: The objective of this study was to determine the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor (HER2), Ki67 and their correlation with other prognostic factors in invasive ductal carcinoma of breast. Subject and method: A retrospective and prospective descriptive study on 175 patients with invasive ductal carcinoma of breast at the 108 Military Central Hospital from May 2019 to September 2021. The status of ER, PR, HER2 and Ki67 expression was examined by immunochemistry. Result: The mean age of the patients was 53.3 ± 12.5 years. The common rate of 2 - 5cm tumor was (95/175) 54.3%. The percentage of cases with tumor grade 2 was the highest at (90/175) 51.4%. The expression of ER, PR, HER2, Ki67 (≥ 14%) were found positive in 53.7%, 51.4%, 33.1%, and 57.7%, respectively. We observed significant correlation between age and ER, PR, HER2 expression (p 0.05). A significant correlation was observed between tumor size and ER, PR expression (p<0.05). Histological grade was related to ER, Ki67 expression (p<0.05).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here